WO2008053310A2 - Traitement de farine et semoule de céréale pour une consommation par des patients coeliaques - Google Patents

Traitement de farine et semoule de céréale pour une consommation par des patients coeliaques Download PDF

Info

Publication number
WO2008053310A2
WO2008053310A2 PCT/IB2007/003245 IB2007003245W WO2008053310A2 WO 2008053310 A2 WO2008053310 A2 WO 2008053310A2 IB 2007003245 W IB2007003245 W IB 2007003245W WO 2008053310 A2 WO2008053310 A2 WO 2008053310A2
Authority
WO
WIPO (PCT)
Prior art keywords
transglutaminase
lysine
gliadin
cereal
flour
Prior art date
Application number
PCT/IB2007/003245
Other languages
English (en)
Other versions
WO2008053310A3 (fr
Inventor
Mauro Rossi
Carmela Gianfrani
Rosa Anna Siciliano
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Priority to US12/312,240 priority Critical patent/US9730458B2/en
Priority to CA2667834A priority patent/CA2667834C/fr
Priority to EP07848833.5A priority patent/EP2094860B1/fr
Publication of WO2008053310A2 publication Critical patent/WO2008053310A2/fr
Publication of WO2008053310A3 publication Critical patent/WO2008053310A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/268—Hydrolysates from proteins
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/264—Vegetable proteins
    • A21D2/265—Vegetable proteins from cereals, flour, bran
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D6/00—Other treatment of flour or dough before baking, e.g. cooling, irradiating, heating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A23L5/25—Removal of unwanted matter, e.g. deodorisation or detoxification using enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A23L7/107—Addition or treatment with enzymes not combined with fermentation with microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Definitions

  • the present invention relates to the enzymatic modification of cereal products for food and/or dietetic use.
  • Celiac disease or gluten-sensitive enteropathy is one of the most widespread forms of food intolerance.
  • the disease manifests itself following the ingestion of gliadin which is the major protein constituent of wheat gluten, or of analogous proteins found in other commonly used cereals such as barley, rye and oats.
  • gliadin which is the major protein constituent of wheat gluten, or of analogous proteins found in other commonly used cereals such as barley, rye and oats.
  • the intolerance is diagnosed within the first three years of life though there are cases in which it manifests belatedly or is completely asymptomatic.
  • Celiac disease is of great epidemiological importance: in Europe it is calculated that the rate ratio of reported cases is 1 :1000 live births, but if latent and asymptomatic cases are also considered, the frequency in reality becomes higher, reaching a rate ratio of 1 :200 (Maki et al, 2003).
  • celiacs suffer from serious malabsorption syndromes (diarrhoea, weight loss, growth retardation, sideropenic anemia, steatorrhea), while a histological examination of the small intestinal mucosa, where lesions are located, shows hyperplasia of the crypts and varying degrees of atrophy of the intestinal villi.
  • mucosal lesions are the product of an altered immune response to gliadin.
  • An analysis of biopsies taken from celiac patients at fasting has highlighted that in these mucosae a massive lymphocyte infiltration exists both in the lamina itself, with a prevalence of CD4 + helper T cells, and in the epithelium above, with largely cytotoxic CD8 + cells.
  • Another important sign of immune activation observed is the increase in cells expressing the interleukin-2 receptor, required for the process of lymphocyte proliferation.
  • the increased binding affinity is believed to be due to the presence of a new negative charge on the gliadin peptide.
  • the deamidated gliadin peptide-histocompatibility molecule complex exposed on the surface of antigen presenting cells, interacts with receptors on the surface of gliadin-specific T lymphocytes and activates them, with consequent lymphocyte proliferation and secretion of inflammatory cytokines responsible for the mucosal damage (van de WaI et al, 1997; Kim et al, 2004). Therefore, although the molecular mechanisms at the basis of celiac disease are becoming ever clearer, the need is ever more felt in this sector for providing cereal products that are nontoxic to celiacs. In this respect, dietetic products for gluten- sensitive people are currently prepared exclusively with flour derived from rice or maize.
  • the approach of the invention is completely different i.e. it allows products to be treated and to be detoxified before their consumption by celiacs, by using the enzyme transglutaminase (protein-glutamine: amine ⁇ -glutamyl-transferase, EC 2.3.2.13) whose bacterially derived form (mTG) is already used in the food industry.
  • This enzyme (mTG) is already in use for cereal based products, or derivatives thereof to increase the compactness of the treated product (Collar et al, 2005).
  • Other uses of mTG include its use for increasing, the nutritional value of gluten by the introduction of lysine or dipeptides of lysine (Yokoyama, 2004). Description of the figures Figure 1. Mass spectrum MALDI-TOF of the 56-68 peptide of ⁇ -gliadin after transamidation with lysine. The satellite ions are due to sodium and potassium adducts.
  • results given in the figure represent the mean ⁇ SD for the results obtained on testing the 12 lymphocyte cell lines defined in Table 1 ; the experiments for each line were repeated at least 3 times. The results were analysed by ANOVA and Tukey's test to verify the statistical significance (P ⁇ 0.05). *: different from ctrB ⁇ tTG; #: different from K+ tTG. SUMMARY
  • the present invention relates to a method for treating cereal products and their derivatives containing prolamin, comprising an enzymatic treatment with transglutaminase (amine ⁇ -glutamyl-transferase EC 2.3.2.13) under conditions that favour transamidation of the glutamine residues in a peptide chain lowering the efficiency of a concomitant deamidation.
  • the treatment relates to prolamins which comprise or consist of gluten and/or gliadin. Both tissue and microbial transglutaminases can be used, either of extractive or recombinant nature, but preferably being food-grade.
  • the reaction takes place in the presence of an alkylated derivative of lysine or of a primary amine: preferably said alkylated derivative of lysine comprises a short chain Ci-C 4 alkyl and is preferably an alkyl, preferably methyl, ester of lysine.
  • the method is particularly suitable for eliminating the toxicity, for celiac patients, of cereal products and derivatives of oats, wheat, barley, rye and is also applicable directly to flour or to semolina.
  • the method therefore is usable industrially to detoxify flour before being used in the preparation of food and/or dietetic products.
  • the invention relates to a method that uses the catalytic activity of transglutaminase (protein-glutamine: amine ⁇ -glutamyl-transferase EC 2.3.2.13), preferably microbial transglutaminase, to modify prolamins derived from cereals so as to lower the immunostimulatory capacity of some types of prolamins towards intestinal T lymphocytes of celiac patients, responsible for gluten-sensitive enteropathy.
  • transglutaminase protein-glutamine: amine ⁇ -glutamyl-transferase EC 2.3.2.13
  • microbial transglutaminase preferably microbial transglutaminase
  • the process of the present invention exploits a property of the transglutaminase enzyme, identified for the first time by the present inventors, which is activated by using the enzyme in the presence of a substrate (i.e. the prolamin to be modified, present in flour or in the cereal derivative) and of an alkylated derivative of lysine, preferably under basic conditions.
  • a substrate i.e. the prolamin to be modified, present in flour or in the cereal derivative
  • an alkylated derivative of lysine preferably under basic conditions.
  • the transglutaminase enzyme normally catalyses the acyl transfer reaction between residues of lysine and glutamine within a protein chain, hence leading to the formation of intermolecular isopeptide bonds which are important in various biological processes such as blood clot formation.
  • the inventors have identified the reaction conditions under which the transglutaminase enzyme in the presence of a non-proteic amino group donor (i.e. free) drives the high efficiency transamidation with formation of an isopeptide bond while at the same time virtually rendering the efficiency of the parallel deamidation reaction equal to zero.
  • microbial transglutaminase being a food-grade enzyme
  • an amino group donor such as a primary amine or a lysine derivative, preferably an alkylated derivative of lysine, even more preferably a methyl ester of lysine.
  • a preferred aspect of the invention relates to a method for the treatment of farinaceous cereal products (flour and semolina) and their derivatives which comprises an enzymatic treatment with transglutaminase under conditions that favour the transamidation of amino acid residues of a prolamin compound and render to zero the efficiency of the deamidation reaction.
  • Said conditions are the presence of a donor of alkylated amino groups such as a primary amine or a lysine derivative, preferably an alkylated derivative of lysine, even more preferably a methyl ester of lysine.
  • the term "cereal products” means farinaceous products, semolina of various grades obtained from cereals preferably wheat, barley, rye and oats. Also included are derivatives of said cereals, obtained by chemical or physicochemical treatment of flour, semolina, whole grains or comminuted grain, such as protein extracts comprising gluten and/or gliadin, peptic-tryptic digests or wheat starch which can contain gluten as contaminant.
  • the method becomes extremely interesting when prolamin product comprises gluten and/or gliadin in that the treatment of the present invention blocks the highly immunoreactive fractions of cereal products responsible for celiac disease.
  • the invention also extends to prolamins other than gliadin which can be treated under the same reaction conditions identified in the present patent and whose toxicity can be completely lowered by the method of the invention.
  • tissue transglutaminases from other animal (Sano et al 1996), plant (Serafini-Fracassini and Del Duca, 2002) and microbial (mTG) (Iranzo et al 2002) sources can be used.
  • Microbial transglutaminases such as those described in Yokoyama K. et al., 2004, are preferred: in this respect they have the advantage of not requiring Ca ++ as co-factor.
  • mTG of Streptomyces mobarensis which can be extractive or recombinant (Zhu et al, 1995) and which exists in food-grade form.
  • Other mTGs are usable, although mTGs which have lysine as the natural substrate are preferred.
  • the enzyme is used in quantities normally employed by the expert of the art, preferably in quantities of about 1-10 U/g of substrate.
  • the enzymatic reaction with mTG proceeds for at least one hour at a temperature above 4°C, or, preferably, at a temperature above 25°C.
  • the product to be treated is dissolved in an aqueous suspension, in the case of flour, at concentrations not higher than 300 mg/ml.
  • the amino-groups donor is preferably an alkylated derivative of lysine, being preferably an alkyl ester of lysine, among which, short chain Ci-C 4 alkyls are particularly preferred.
  • the alkyl ester of lysine is added or dissolved in quantities of between 5 and 200 mM.
  • Substrates comprising with the term: "flour”, prolamin extracts or purified proteins comprising gluten, avenin, hordein or secalin and hence, more generally, any derivative of wheat, oats, barley, rye preferably in the form of flour, semolina, powder or granules, for food use.
  • the method can be implemented directly on the flour, semolina or extracts to be detoxified. It has been already reported in the literature that mTG treatment produces high quality flour which maintain optimum organoleptic, viscoelastic and mechanical qualities (Collar, 2005).
  • the direct treatment of a food product can be subdivided into the following steps:
  • an amino-group donor as aforedefined, being preferably a lysine alkylated derivative or, preferably, a lysine alkyl ester derivative, preferably at a concentration between 5 and 200 mM in the case of the methyl ester of lysine;
  • the substrate be a powder or semolina
  • the products obtained from the reaction are chemically modified and also exhibit antigenic properties different from those of untreated products or products treated in other conditions, and are found to be less able or completely unable to stimulate the lymphocytes of celiac patients in vitro.
  • they have at least one glutamine residue, residing in the peptide corresponding to the p58-68 ⁇ - gliadin fragment which is involved in the isopeptide bond with lysine containing an alkyl group in the ⁇ position.
  • gliadin-corresponding peptides of prolamins other than gliadin such as: avenin and/or hordein and/or secalin which are transamidated and involved in an isopeptide bond.
  • the present invention comprises, therefore, products derived and obtainable in accordance with the described process as well as food products containing the modified prolamins as aforedescribed.
  • the enzymatic reaction conditions in the presence of alkylated derivatives of lysine and where there is a total absence of deamidated contaminants, can be extended to other uses of tissue or microbial transglutaminase where a higher efficiency of transamidation rather than deamidation is preferable.
  • the invention extends to the use of a transglutaminase (amine ⁇ -glutamyl-transferase EC 2.3.2.13), preferably under alkaline conditions (pH higher than 7.5, preferably between 8 and 9) in the case of tissue transglutaminase (tTG), in the presence of an alkylated derivative of lysine for a high efficiency transamidation and binding through an isopeptide bond of glutamine amino acid residues.
  • the method of the invention is industrially applicable to all processes for preparing specialty or dietetic food products formulated for gluten-sensitive individuals, and comprises a treatment for cereal flour, semolina or derivatives or their mixtures as aforedescribed, in particular using the food-grade enzyme (mTG).
  • PT-gliadin a peptic-tryptic digest of gliadin
  • 20 mg of gliadin are suspended in 200 ⁇ l of 0.2 N HCL pH 1.8 in the presence of pepsin (protein:enzyme ratio 100:1) and incubated for 4 hours at 37°C.
  • the pH is then brought to 8.5 by adding Tris (final concentration 0.125 M). Trypsin is added to the solution (proteirr.enzyme ratio 100:1) and the incubation at 37°C proceeds for a further 2 hours.
  • the reaction is finally stopped by boiling the sample for 10 minutes.
  • the samples are stored at -20 0 C until required.
  • PT-gliadin Deamidation of PT-gliadin. 2mg of PT-gliadin are suspended in 1 ml of 0.125 M Tris/HCL pH 8.5 containing 1 mM calcium chloride, 10 mM dithiotreitol and 200 ⁇ g of tTG. The reaction is carried out at 37°C for 4 hours, then stopped by boiling the sample for 10 minutes. Samples are stored at -2O 0 C until required. Transamidation of PT-gliadin.
  • PT-gliadin (2 mg) and lysine or methyl ester of lysine (20 mM) are suspended in 1 ml of 0.125 M Tris/HCL pH 8.5 containing 1 mM calcium chloride, 10 mM dithiotreitol and 200 ⁇ g tTG.
  • the reaction is carried at 37°C for 4 hours, then stopped by boiling the sample for 10 minutes.
  • the samples are stored at -20 0 C until required.
  • the transamidation reaction is monitored using a synthetic ⁇ -gliadin peptide (residues 56-68, LQLQPFPQLPY) as a model. After the reaction the mass spectra are acquired by accumulating 100 laser shots, using as internal standards the monoisotopic peaks of angiotensin (m/z 931.5154) and of ACTH (m/z 2465.1989) so as to reduce experimental error to less than 20 ppm; the values are reported as monoisotopic masses. Enzymatic treatment of flour.
  • 1.2 g of commercial wheat flour are suspended in 10 ml of water containing 8 U mTG (N-Zyme Biotec GMbH, Darmstadt, Germany) and 20 mM or 2 M lysine or methyl ester of lysine; the reaction is carried at room temperature for 2 hours or for 4 hours at 37°C. Extraction of gliadin.
  • the aqueous flour suspension is transferred into 67 mM sodium phosphate buffer pH 7.6 containing 0.4 M NaCI and extracted by agitating for 30 minutes followed by centrifugation for 15 minutes at 15,50Og.
  • the pellet is recovered and resuspended in 20 ml of an aqueous ethanol solution (70%) and extracted by agitation for 45 minutes, followed by centrifugation for 15 minutes at 15,00Og.
  • the supernatant consisting of gliadin is then lyophilized and stored at - 20 0 C until required.
  • gliadin-specific intestinal T-lymphocyte lines Twelve consenting HLA-DQ2+ adult celiac patients, eight of whom were treated with diet (age range 18-49, mean 29.49) and 4 untreated (age range 18-34, mean 27), were enrolled in the study. Mucosal biopsies from these patients at fasting were digested with collagenase A. The intestinal cells were suspended in RPMI culture medium supplemented with antibiotics, non-essential amino acids, sodium pyruvate, glutamine and inactivated human serum (10%) at a density of 2 x 10 5 /ml.
  • the cells were then stimulated with irradiated (3500 Rad) autologous peripheral blood cells (PBMCs; 1 x 10 6 AnI) and PT-gliadin deamidated by treatment with tTG (50 ⁇ g/ml). Twenty-four hours later fresh medium containing 10 ng/ml IL-15 was added to the cultures. On day 7 the intestinal T cell lines (iTCLs) produced were again stimulated with antigen and PBMCs followed by addition of fresh medium and IL-15 on the following day and at 3-4 day intervals. All the iTCLs obtained were found to be positive for CD4 molecule expression.
  • the T cell lines were tested while in the resting phase using transformed B-lymphoblastoid cells, from the same HLA haplotype, as antigen presenting cells (APCs).
  • APCs antigen presenting cells
  • Irradiated APCs (5 x 10 5 /ml) were incubated for 18 hours with PT-gliadin (50 ⁇ g/ml) in 96-well plates.
  • the iTCLs (1.5 x 10 5 AnI) were added into each plate at a final volume of 200 ⁇ l. After 48 hours of incubation aliquots of the supernatant were collected to determine the IFNy production (inflammatory marker) by ELISA.
  • Example 1 Characterization of structural modifications induced on the peptide by enzymatic treatment
  • Example 2 Assessment of IFN- ⁇ production by lymphocytes of celiac patients following stimulation with the peptides modified according to the invention or to the prior art
  • Transamidation is able to inhibit the immune response towards gliadin in vitro.
  • the ability of the transamidation reaction under alkaline conditions, to inhibit the immune response to gliadin is evaluated by using iTCLs derived from celiac patients.
  • the iTCLs are incubated in the presence of a peptic-tryptic digest of wheat gliadin (PT-gliadin) treated with tTG in the presence or absence of an amino group donor.
  • PT-gliadin peptic-tryptic digest of wheat gliadin treated with tTG in the presence or absence of an amino group donor.
  • microbial transglutaminase is of particular interest, being an already widely used enzyme in the food industry for improving the quality of meat, fish, milk and soya based products (Zhu et al. 1995; Motoki and Seguro 1998).
  • a further advantage of this enzyme is that it does not require calcium as co-factor and it is small in size (MW 38 kDA) thus enabling its potential interaction with glutamine residues even under native conditions.
  • the gliadin fraction was extracted as described in Materials and Methods.
  • the gliadin was then digested with pepsin and trypsin (PT-gliadin).
  • the PT-gliadin preparation was subdivided into two batches one of which was subjected to deamidation reaction with tTG.
  • the different preparations were finally subjected to in vitro testing with the iTCLs.
  • the results, given in Fig 2, relate to the treatment according to protocol a); in this respect no differences were found in terms of efficiency between protocols a) and b).
  • mTG was found to be able to drive a transamidation reaction which inhibits the immunostimulatory activity of gliadin.
  • Electrophoretic analysis of gliadin extracted from flour after enzymatic treatment also indicates that substantial changes in the molecule such as to impair its function in technological processes are not present.
  • Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4: 713-717.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Noodles (AREA)
  • Cereal-Derived Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un procédé enzymatique pour traiter la farine, la semoule et des extraits protéiques issus de céréales connues pour stimuler une réponse immunitaire pathologique chez des patients affectés par la maladie coeliaque (CD). Ledit traitement réduit de façon sensible ou élimine complètement la toxicité du gluten ou de produits analogues issus d'autres céréales. Le procédé utilise l'activité catalytique d'une transglutaminase microbienne et, en particulier, son aptitude à lier des protéines dans la farine ou semoule de céréale à un dérivé alkylé en C1-C4 de la lysine. Après le traitement, lesdites protéines extraites de la farine ont une activité immunostimulatrice sensiblement diminuée dans les lymphocytes T des patients coeliaques.
PCT/IB2007/003245 2006-10-30 2007-10-29 Traitement de farine et semoule de céréale pour une consommation par des patients coeliaques WO2008053310A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/312,240 US9730458B2 (en) 2006-10-30 2007-10-29 Treatment of cereal flour and semolina for consumption by celiac patients
CA2667834A CA2667834C (fr) 2006-10-30 2007-10-29 Traitement de farine et semoule de cereale pour une consommation par des patients coeliaques
EP07848833.5A EP2094860B1 (fr) 2006-10-30 2007-10-29 Traitement de farine et semoule de céréale pour une consommation par des patients coeliaques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002080A ITMI20062080A1 (it) 2006-10-30 2006-10-30 Trattamento di farine di cereali per il consumo alimentare da parte di pazienti celiaci
ITMI2006A002080 2006-10-30

Publications (2)

Publication Number Publication Date
WO2008053310A2 true WO2008053310A2 (fr) 2008-05-08
WO2008053310A3 WO2008053310A3 (fr) 2008-07-31

Family

ID=39284250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003245 WO2008053310A2 (fr) 2006-10-30 2007-10-29 Traitement de farine et semoule de céréale pour une consommation par des patients coeliaques

Country Status (5)

Country Link
US (1) US9730458B2 (fr)
EP (1) EP2094860B1 (fr)
CA (1) CA2667834C (fr)
IT (1) ITMI20062080A1 (fr)
WO (1) WO2008053310A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20091739A1 (it) * 2009-10-12 2011-04-13 Ipafood Srl Produzione di glutine solubile mediante trattamento enzimatico di farina
WO2013156156A1 (fr) * 2012-04-17 2013-10-24 Aesku.Diagnostics Gmbh & Co.Kg Procédé de diagnostic pré-symptomatique de la maladie cœliaque et de la sensibilité au gluten
ITSR20130002A1 (it) * 2013-10-08 2015-04-08 Danilo Ciciulla Nuovo processo industriale di lavorazione per la produzione di alimenti farinacei, destinati a soggetti con malattia celiaca clinicamente manifesta, a base di farine comuni.
ITUB20159412A1 (it) * 2015-12-16 2017-06-16 Consiglio Nazionale Ricerche Procedimento per la preparazione di composizioni con attivita immuno-regolatoria antigene-specifica
IT201800010305A1 (it) 2018-11-13 2020-05-13 Danilo Ciciulla Procedimento per la preparazione di alimenti a base di farina di grano destinati a soggetti celiaci o affetti da gluten sensitivity
WO2021250712A1 (fr) * 2020-06-09 2021-12-16 Dr. Schär S.P.A. Procédé de préparation d'un mélange et produits alimentaires dérivés

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5823234A (ja) 1981-08-04 1983-02-10 Hino Motors Ltd 車両に使用されるディ−ゼル機関の燃料噴射装置
JPS5828234A (ja) * 1981-08-08 1983-02-19 Snow Brand Milk Prod Co Ltd タンパク素材の製造方法
FR2627062B1 (fr) 1988-02-12 1991-08-16 Bongrain Sa Utilisation dans les industries alimentaires de micro-organismes exprimant les genes de transglutaminase, pour texturer des melanges proteiques
JPH079707A (ja) 1993-06-25 1995-01-13 Canon Inc 印刷装置
JP3163339B2 (ja) * 1993-09-17 2001-05-08 味の素株式会社 食用蛋白の改質
EP0685164A1 (fr) 1994-06-03 1995-12-06 Asama Chemical Co., Ltd. Additif alimentaire
EP0745670B1 (fr) 1994-10-11 2004-06-23 Ajinomoto Co., Inc. Transglutaminase stabilisee et preparation enzymatique contenant cette transglutaminase
JP3582265B2 (ja) * 1996-11-28 2004-10-27 味の素株式会社 改質穀粉及びこれを使用した穀粉加工食品
JPH10276695A (ja) 1997-04-11 1998-10-20 Ajinomoto Co Inc めん類の製造方法
JPH11243843A (ja) 1998-02-27 1999-09-14 Ajinomoto Co Inc パン類の製造方法及びパン類製造用酵素製剤
WO1999056698A2 (fr) 1998-05-06 1999-11-11 Københavns Universitet Traitement de la maladie caeliaque
EP1085023A1 (fr) 1999-09-20 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Réticulation partielle de protéines avec de la transglutaminase
EP1263296A2 (fr) 2000-03-06 2002-12-11 Campina Melkunie B.V. Preparation de proteines
DE10046605A1 (de) * 2000-09-20 2002-03-28 Roehm Enzyme Gmbh Verwendung von Transglutaminasen zur Herstellung von weizenarmen Backwaren
DE10346764A1 (de) 2002-10-07 2004-04-15 Piemonte Import Warenhandelsgesellschaft Mbh Mit Transglutaminase fermentierte Vorteigprodukte und die Verwendung von Transglutaminase bei deren Herstellung
KR100513699B1 (ko) 2004-11-27 2005-09-08 강동오 제빵 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20091739A1 (it) * 2009-10-12 2011-04-13 Ipafood Srl Produzione di glutine solubile mediante trattamento enzimatico di farina
WO2013156156A1 (fr) * 2012-04-17 2013-10-24 Aesku.Diagnostics Gmbh & Co.Kg Procédé de diagnostic pré-symptomatique de la maladie cœliaque et de la sensibilité au gluten
EP2839290B1 (fr) * 2012-04-17 2019-03-06 Aeneas GmbH & Co. KG Procédé de diagnostic pré-symptomatique de la maladie c liaque et de la sensibilité au gluten
US10571466B2 (en) 2012-04-17 2020-02-25 Aeneas Gmbh & Co. Kg Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity
US11686728B2 (en) 2012-04-17 2023-06-27 Aeneas Gmbh & Co. Kg Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity
ITSR20130002A1 (it) * 2013-10-08 2015-04-08 Danilo Ciciulla Nuovo processo industriale di lavorazione per la produzione di alimenti farinacei, destinati a soggetti con malattia celiaca clinicamente manifesta, a base di farine comuni.
WO2015052665A1 (fr) 2013-10-08 2015-04-16 Ciciulla Danilo Procédé de préparation de produits alimentaires à base de farine semi-finis comprenant un élément présentant une activité trans-glutaminase et une source de lysine
ITUB20159412A1 (it) * 2015-12-16 2017-06-16 Consiglio Nazionale Ricerche Procedimento per la preparazione di composizioni con attivita immuno-regolatoria antigene-specifica
WO2017103808A1 (fr) * 2015-12-16 2017-06-22 Consiglio Nazionale Delle Ricerche Procédé de préparation de compositions immunorégulatrices, à activité spécifique aux antigènes
IT201800010305A1 (it) 2018-11-13 2020-05-13 Danilo Ciciulla Procedimento per la preparazione di alimenti a base di farina di grano destinati a soggetti celiaci o affetti da gluten sensitivity
WO2021250712A1 (fr) * 2020-06-09 2021-12-16 Dr. Schär S.P.A. Procédé de préparation d'un mélange et produits alimentaires dérivés

Also Published As

Publication number Publication date
EP2094860B1 (fr) 2016-01-13
WO2008053310A3 (fr) 2008-07-31
US9730458B2 (en) 2017-08-15
EP2094860A2 (fr) 2009-09-02
CA2667834A1 (fr) 2008-05-08
CA2667834C (fr) 2017-04-18
US20100221384A1 (en) 2010-09-02
ITMI20062080A1 (it) 2008-04-30

Similar Documents

Publication Publication Date Title
Wieser et al. The biochemical basis of celiac disease
Molberg et al. Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease
Scherf et al. Novel approaches for enzymatic gluten degradation to create high-quality gluten-free products
US9730458B2 (en) Treatment of cereal flour and semolina for consumption by celiac patients
De Angelis et al. Mechanism of degradation of immunogenic gluten epitopes from Triticum turgidum L. var. durum by sourdough lactobacilli and fungal proteases
Cabrera-Chávez et al. Maize prolamins resistant to peptic-tryptic digestion maintain immune-recognition by IgA from some celiac disease patients
KR102702879B1 (ko) 셀리악 스프루 질환 치료용 조성물 및 방법
EP1779115B1 (fr) Procédé de dosage du gluten
JP2021073236A (ja) グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法
Brzozowski Immunoreactivity of wheat proteins modified by hydrolysis and polymerisation
Di Stasio et al. Comparative analysis of in vitro digestibility and immunogenicity of gliadin proteins from durum and einkorn wheat
EP1075267A2 (fr) Traitement de la maladie caeliaque
US10457929B2 (en) Compositions for the treatment of gluten intolerance and uses thereof
De Vincenzi et al. In vitro assessment of acetic‐acid‐soluble proteins (glutenin) toxicity in celiac disease
Wieser et al. Celiac disease-multidisciplinary approaches
Chirdo et al. Cereal proteins: immunostimulatory and toxic peptides
JP2009148248A (ja) 低アレルゲン化剤
WO2022045151A1 (fr) Procédé de production d'une protéine modifiée
Nehra et al. Celiac disease and its therapy: current approaches and new advances
De Vincenzi et al. Agglutinating activity of alcohol-soluble proteins from quinoa seed flour in celiac disease
Ćirković Veličković et al. Food Allergens Digestibility
Pulido Immune‐Mediated Adverse Reactions to Dietary Proteins
KR20240152328A (ko) 셀리악 스프루 질환 치료용 조성물 및 방법
Luan Development of transgenic soybeans encoding major peanut allergens Ara h 2 or Ara h 6 as a model to evaluate potential matrix effects relative to the risk assessment of GM crops
PULIDO IMMUNE-MEDIATED ADVERSE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07848833

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2667834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12312240

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007848833

Country of ref document: EP